

#### NC MEDICAID DIVISION OF HEALTH BENEFITS PREFERRED DRUG LIST REVIEW PANEL MEETING

# AGENDA

Thursday, October 10, 2024 1:00 p.m. – 5:00 p.m. Virtual Online Meeting

#### I. Welcome

- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets once per quarter, in addition to reviewing every PDL category at least once per calendar year. Public comments during the 30-day public comment period are allowed for categories that the State designates on the publicly posted document (any category with proposed additions and/or removals). Speakers at the PDL Panel meeting are only allowed for categories listed on the agenda for that meeting. The categories below contain recommendations that will require a vote by the PDL Panel. Those categories that are highlighted have no State recommendations but are open for discussion:

# ALZHEIMER'S AGENTS

### **ANALGESICS**

1. NSAIDs

## ANTICONVULSANTS

1. Second Generation

### ANTI-INFECTIVES – SYSTEMIC

- 1. Penicillins, Cephalosporins and Related
- 2. Tetracycline Derivatives

### **BEHAVIORAL HEALTH**

- 1. Selective Serotonin Reuptake Inhibitor (SSRI)
- 2. Antihyperkinesis / ADHD
- 3. Atypical Antipsychotics Oral, Transdermal

### **CARDIOVASCULAR**

- 1. Angiotensin II Receptor / Neprilysin Blocker Combinations
- 2. Cholesterol Lowering Agents
- 3. Non-Dihydropyridine Calcium Channel Blockers

## **CENTRAL NERVOUS SYSTEM**

- 1. Antiparkinson and Restless Leg Syndrome Agents
- 2. Multiple Sclerosis- Injectable
- 3. Amyotrophic Lateral Sclerosis (ALS) Agents
- 4. Tobacco Cessation

### **ENDOCRINOLOGY**

- 1. Premixed Rapid Combination Insulin
- 2. Premixed 70/30 Combination Insulin
- 3. GLP-1 Receptor Agonists and Combinations
- 4. 2<sup>nd</sup> Generation Sulfonylureas
- 5. DPP-IV Inhibitors and Combinations
- 6. Meglinitides
- 7. SGLT-2 Inhibitors and Combinations

## **GASTROINTESTINAL**

- 1. Antiemetic-Antivertigo Agents
- 2. Bile Acid Salts
- 3. Histamine-2 Receptor Antagonists
- 4. Ulcerative Colitis, Oral

### **GENITOURINARY / RENAL**

- 1. Electrolyte Depleters (Kidney Disease)
- 2. Benign Prostatic Hyperplasia Treatments
- 3. Urinary Antispasmodics

### **HEMATOLOGICS**

1. Hematopoietic Agents

### **OPHTHALMICS**

- 1. Antibiotics
- 2. Beta Blocker Agents / Combinations

## **OTIC**

1. Anti-Inflammatory

### **RESPIRATORY**

- 1. Beta-Adrenergic Handheld, Short-Acting
- 2. Inhaled Corticosteroids (also an off cycle review)
- 3. Low Sedating Antihistamines

## **TOPICALS**

#### 1. NSAIDs

- 2. Antibiotics Vaginal
- 3. Antifungals
- 4. Immunomodulators, Atopic Dermatitis
- 5. Imidazoquinolinamines
- 6. High-Potency Steroids

## **MISCELLANEOUS**

- 1. Weight Management Agents, Incretin Mimetics
- 2. Weight Management Agents, Non-Incretin Mimetics
- 3. Immunomodulators, Asthma
- 4. Estrogen Agents, Combinations
- 5. Glucocorticoid Steroids, Oral
- 6. Cytokine and CAM Antagonists (previously listed as Immunomodulators, Systemic)
- 7. Immunosuppressants
- 8. Movement Disorders
- 9. Opioid Antagonists
- 10. Opioid Dependence (off cycle change)
- V. Closing comments and adjournment